Perspective
Our work in Perspective
-
The Unequal Causes and Costs of Dementia
Dementia and its costs aren’t equally borne by all populations. Studies indicate that, compared to older non-Hispanic white adults, older Black adults are about twice as likely to have dementia, and older Hispanic adults about one and one-half times as likely.
Categorized in -
It’s Time to Let Pharmacists Prescribe COVID-Fighting Pills Like Paxlovid
To reduce hospitalization and death, pharmacists should have the same prescribing abilities as doctors for COVID anti-viral drugs Paxlovid and Lagevrio, USC School of Pharmacy
Dean Vassilios Papadopoulos writes in a new MarketWatch op-ed.Categorized in -
Comments to the Federal Trade Commission on Pharmacy Benefit Managers
Researchers at the USC Schaeffer Center have been studying the pharmaceutical distribution system since 2016; these comments about PBMs draw on that body of research.
Categorized in -
I Wrongly Expected COVID to Fade Last Summer — Here’s What to Expect This Time
After believing the pandemic would be under control by Memorial Day 2021, Schaeffer Center expert Geoffrey Joyce writes why he believes COVID is nowhere near under control.
Categorized in -
Patients Deserve Immediate Access to FDA-Approved Innovations — Not Bureaucratic Restrictions
Nonresident Senior Fellow Joe Grogan argues that the FDA approval process is slowing down drug innovation.
Categorized in -
Here’s How Public Health Messaging Can Help With the Next Phase of the Pandemic
As COVID-19 cases increase and officials warn of a potential new surge, confusion still bedevils our public health messaging.
Categorized in -
Will the Rise of Work From Home Improve Our Health?
As the pandemic becomes endemic, major companies have announced varying polices about the future of remote work. Matthew Kahn argues that government and industry should accommodate WFH or hybrid plans because the benefits are manifold.
Categorized in -
Value Defects In The Health Services Sector
As of 2021, US health care expenditures exceed $3.8 trillion. It’s no secret that health care is nearly as wasteful in spending on value defects—behaviors that needlessly reduce quality, negatively impact the patient experience, or add to total costs of care—as it is in delivering clinical benefits.
Categorized in -
Racial Disparities in Accessing Treatment for Substance Use Highlights Work to Be Done
Older Americans are increasingly seeking treatment for substance use disorders with older Black Americans who start treatment being much more likely to have their treatment terminated and not finish compared to white adults.
Categorized in -
Who Is Really Driving Up Insulin Costs?
In the long term, capping insulin payments at $35 a month is just shuffling the deck rather than changing the game of insulin costs.
Categorized in